AbbVie Says Buying Spree Will Add R&D Heft Needed For Long-Term Growth

Cerevel Acquisition For $8.7bn Closely Follows $10.1bn ImmunoGen Buyout

opportunity
AbbVie thinks Cerevel's pipeline offers multiple potential blockbuster sellers • Source: Shutterstock

More from Strategy

More from Business